Frequency and Domain Specificity of Toxin-Neutralizing Paratopes in the Human Antibody Response to Anthrax Vaccine Adsorbed
- 1 May 2009
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 77 (5), 2030-2035
- https://doi.org/10.1128/iai.01254-08
Abstract
Protective antigen (PA) is the cell surface recognition unit of the binary anthrax toxin system and the primary immunogenic component in both the current and proposed “next-generation” anthrax vaccines. Several studies utilizing animal models have indicated that PA-specific antibodies, acquired by either active or passive immunization, are sufficient to protect against infection with Bacillus anthracis . To investigate the human antibody response to anthrax immunization, we have established a large panel of human PA-specific monoclonal antibodies derived from multiple individuals vaccinated with the currently approved anthrax vaccine BioThrax. We have determined that although these antibodies bind PA in standard binding assays such as enzyme-linked immunosorbent assay, Western blotting, capture assays, and dot blots, less than 25% are capable of neutralizing lethal toxin (LT) in vitro. Nonneutralizing antibodies also fail to neutralize toxin when present in combination with other nonneutralizing paratopes. Although neutralizing antibodies recognize determinants throughout the PA monomer, they are significantly less common among those paratopes that bind to the immunodominant amino-terminal portion of the molecule. These findings demonstrate that PA binding alone is not sufficient to neutralize LT and suggest that for an antibody to effectively block PA-mediated toxicity, it must bind to PA such that one of the requisite toxin functions is disrupted. A vaccine design strategy that directed a higher percentage of the antibody response toward neutralizing epitopes may result in a more efficacious vaccine for the prevention of anthrax infection.Keywords
This publication has 19 references indexed in Scilit:
- Domain specificity of the human antibody response to Bacillus anthracis protective antigenVaccine, 2008
- Paratope diversity in the human antibody response to Bacillus anthracis protective antigenMolecular Immunology, 2008
- Anthrax Protective Antigen Cleavage and Clearance from the Blood of Mice and RatsInfection and Immunity, 2007
- Immunogenicity of a subunit vaccine against Bacillus anthracisVaccine, 2007
- Correlation of antigenic epitope and antibody gene usage in the human immune response to Streptococcus pneumoniae type 23F capsular polysaccharideClinical Immunology, 2004
- Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal AntibodyJournal of Biological Chemistry, 2003
- AnthraxAnnual Review of Microbiology, 2001
- Hydrophobic Residues Phe552, Phe554, Ile562, Leu566, and Ile574 Are Required for Oligomerization of Anthrax Protective AntigenBiochemical and Biophysical Research Communications, 2001
- Anthrax ToxinCritical Reviews in Microbiology, 2001
- Gapped BLAST and PSI-BLAST: a new generation of protein database search programsNucleic Acids Research, 1997